

# NOCA

National Ovarian  
Cancer Audit

NOCA, Clinical Effectiveness Unit

Royal College of Surgeons of England  
38-43 Lincoln's Inn Fields  
London WC2A 3PE

E: [OvarianCancerAudit@rcseng.ac.uk](mailto:OvarianCancerAudit@rcseng.ac.uk)

T: 020 7869 6606  [noca-natcan.bsky.social](https://twitter.com/noca-natcan)

 [NOCA\\_NATCAN](https://x.com/NOCA_NATCAN)  [LinkedIn](https://www.linkedin.com/company/noca-natcan)

## NOCA Newsletter, March 2026

### Want to hear more?

The NOCA is part of the National Cancer Audit Collaborating Centre (NATCAN). If you want to find out more about NATCAN visit our [new website](#). If you would like to receive regular updates send us an email [NATCAN@rcseng.ac.uk](mailto:NATCAN@rcseng.ac.uk)

### Update on NOCA QI intervention

So far NOCA has received responses from half of all Gynaecological Cancer Systems in England and Wales (response rate of 49%) for its Quality Improvement intervention. Our QI intervention focuses on the following performance indicator '**Percentage of women diagnosed with ovarian cancer within 28 days after an emergency admission who receive any treatment (surgery and/or chemotherapy) within 3 months from diagnosis**' and we have contacted the clinical leads at all Gynaecological Cancer Systems in England and Wales with details of their results. All the responses received will be compiled and shared in the first half of 2026, with a summary of challenges and limitations experienced by systems and examples of best practice. Please take a look at the [QI intervention poster](#) on our website, which includes further information. If you are not sure if your Gynaecological Cancer System has responded yet, please check our live [response log](#). By working collaboratively, we hope to improve the treatment rates for women diagnosed following an emergency admission.

### NOCA State of the Nation Report 2026


The 3rd **NOCA State of the Nation Report 2026** is due to be published on the [NATCAN website](#) on **11th June 2026**, subject to clearance and sign-off. Thank you to those members of the NOCA Clinical Reference Group who have provided feedback and comments on the draft report. This report will include women diagnosed with ovarian cancer in England in 2023 and Wales in 2024. This year we will include two new indicators: 'Receipt of surgery' and 'Receipt of chemotherapy'. NOCA will also publish a patient and public version of the report on the same date.

### Research news

Have you seen the recent NOCA publication in the International Journal of Gynecological Cancer? Read [Determinants and outcomes of ovarian cancer diagnosis following an emergency presentation: a systematic review](#) on our website. Congratulations to lead author, Dr Georgia Zachou, NOCA Clinical Fellow!

### April data dashboard

The next [NOCA quarterly data dashboard](#) will be published on the NATCAN website on **9th April 2026**, subject to clearance and sign-off. This report includes more recent data, patients in England diagnosed up to **September 2024**.



### Conferences/Events

Members of the NOCA Project Team were present at the **ESGO 2026 Congress** in Copenhagen 26-28th February, where Dr Georgia Zachou, NOCA's Clinical Fellow, presented the latest results on the detrimental effect of emergency presentations on survival outcomes in ovarian cancer. In addition, Dr Georgia Zachou attended the **BGCS trainees and trainers' day** on 30th January to update the clinical community on the NOCA QI intervention.